Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy

MJ Ramaiah, AD Tangutur, RR Manyam - Life sciences, 2021 - Elsevier
The role of genetic and epigenetic factors in tumor initiation and progression is well
documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA …

The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms

R Meech, DG Hu, RA McKinnon… - Physiological …, 2019 - journals.physiology.org
UDP-glycosyltransferases (UGTs) catalyze the covalent addition of sugars to a broad range
of lipophilic molecules. This biotransformation plays a critical role in elimination of a broad …

Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the …

AJ Armstrong, S Halabi, J Luo, DM Nanus… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which
leads to ligand-independent constitutive activation that is not inhibited by anti-androgen …

Androgen signaling in prostate cancer

C Dai, H Heemers, N Sharifi - Cold Spring …, 2017 - perspectivesinmedicine.cshlp.org
The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer.
Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has …

[HTML][HTML] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)

T Chandrasekar, JC Yang, AC Gao… - … andrology and urology, 2015 - ncbi.nlm.nih.gov
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Aldo-keto reductases and cancer drug resistance

TM Penning, S Jonnalagadda, PC Trippier… - Pharmacological …, 2021 - ASPET
Human aldo-keto reductases (AKRs) catalyze the NADPH-dependent reduction of carbonyl
groups to alcohols for conjugation reactions to proceed. They are implicated in resistance to …

Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer

M Zou, R Toivanen, A Mitrofanova, N Floch, S Hayati… - Cancer discovery, 2017 - AACR
Current treatments for castration-resistant prostate cancer (CRPC) that target androgen
receptor (AR) signaling improve patient survival, yet ultimately fail. Here, we provide novel …

Abiraterone and increased survival in metastatic prostate cancer

JS De Bono, CJ Logothetis, A Molina… - … England Journal of …, 2011 - Mass Medical Soc
Background Biosynthesis of extragonadal androgen may contribute to the progression of
castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor …

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

T Karantanos, PG Corn, TC Thompson - Oncogene, 2013 - nature.com
Prostate cancer is the second-leading cause of cancer-related mortality in men in Western
societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer …

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

AM Moilanen, R Riikonen, R Oksala, L Ravanti… - Scientific reports, 2015 - nature.com
Activation of androgen receptor (AR) is crucial for prostate cancer growth. Remarkably, also
castration-resistant prostate cancer (CRPC) is dependent on functional AR and several …